SYM FINANCIAL Corp Sells 1,574 Shares of Amgen Inc. $AMGN

SYM FINANCIAL Corp decreased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 57.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,155 shares of the medical research company’s stock after selling 1,574 shares during the period. SYM FINANCIAL Corp’s holdings in Amgen were worth $326,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC raised its holdings in shares of Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after purchasing an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC grew its position in Amgen by 10.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after purchasing an additional 114 shares in the last quarter. Pure Financial Advisors LLC increased its stake in Amgen by 15.6% in the 2nd quarter. Pure Financial Advisors LLC now owns 4,822 shares of the medical research company’s stock valued at $1,346,000 after buying an additional 652 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Amgen by 11.5% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 543,933 shares of the medical research company’s stock worth $151,872,000 after buying an additional 56,183 shares in the last quarter. Finally, Triad Wealth Partners LLC purchased a new position in shares of Amgen in the 2nd quarter worth approximately $206,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on AMGN shares. Guggenheim increased their price target on Amgen from $288.00 to $305.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. UBS Group upped their price objective on Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a research note on Monday. Truist Financial lifted their target price on Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research note on Thursday, January 8th. Cantor Fitzgerald increased their price target on shares of Amgen from $305.00 to $315.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. Finally, Wall Street Zen upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Amgen presently has a consensus rating of “Moderate Buy” and a consensus price target of $342.45.

Insider Activity

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the transaction, the senior vice president owned 7,225 shares in the company, valued at $2,436,703.50. This trade represents a 30.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the transaction, the executive vice president directly owned 41,923 shares of the company’s stock, valued at $14,120,924.09. The trade was a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 10,908 shares of company stock worth $3,674,966. 0.76% of the stock is owned by corporate insiders.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $341.88 on Friday. The firm has a market capitalization of $184.10 billion, a PE ratio of 26.42, a P/E/G ratio of 3.02 and a beta of 0.45. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. The company has a 50-day moving average price of $332.60 and a two-hundred day moving average price of $309.22. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $353.25.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.01 by $0.63. The company had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.58 earnings per share. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. Amgen’s dividend payout ratio is 73.57%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.